Nucleos(t)ide analogs (NUCs) are recommended when both are fulfilled in the absence of hepatocellular carcinoma (HCC) or cirrhosis; (1) elevated serum hepatitis B virus (HBV)-DNA (≥20,000 IU/mL for hepatitis B e antigen–positive chronic hepatitis B [CHB] or ≥2000 IU/mL for hepatitis B e antigen–negative CHB) and (2) serum alanine aminotransferase ≥2× upper limit of normal.1 Therefore, many patients still remain untreated. Such untreated patients have so called “minimally active CHB,” where serum HBV-DNA is persistently >2000 IU/mL and other parameters for NUCs are below the criteria.2 There have been little data concerning their prognosis.
Bibliographical noteFunding Information:
Funding This research was in part supported by a fund (2019-ER5102-00) by Research of Korea Centers for Disease Control and Prevention. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© 2019 AGA Institute
All Science Journal Classification (ASJC) codes